Pharmacy Europe – High hopes for new MRSA antibiotic.
A new antibiotic that shows promise in treating the superbug MRSA and related infections is poised to enter the market after phase III ASSIST trials in the US.
Intravenous iclaprim, a novel antibiotic, is reported by manufacturer Arpida to show high clinical cure rates similar to those of the comparator drug, linezolid.
The test results were gathered from the ASSIST-1 and ASSIST-2, (Arpida’s skin and skin structure infection study) pivotal Phase III studies involving a total of 991 patients.
Data from the studies also show that iclaprim exhibited a high eradication rate for MRSA (76.4%), which was comparable to that of linezolid (78.7%).
